1-11 of 11
Jonas S. Heitmann
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Trial in Progress: Phase I Trial Evaluating an Immunopeptidome-Defined Multi-Peptide Vaccine Against Acute Myeloid Leukemia Stem and Progenitor Cells

Susanne Jung, Annika Nelde, Yacine Maringer, Monika Denk, Lisa Zieschang, Christine Kammer, Melek Özbek, Christopher Hackenbruch, Jonas S. Heitmann, Helmut R. Salih, Juliane S. Walz
Journal: Blood
Blood (2024) 144 (Supplement 1): 1504.1.
https://doi.org/10.1182/blood-2024-198082
Published: 2024
Journal Articles

A Phase 1, Open-Label, Dose Escalation and Dose Expansion Study of Cln-049 for the Treatment of Acute Myeloid Leukemia Patients with Measurable Residual Disease

Jonas S. Heitmann, Juliane S. Walz, Helmut R. Salih, Klaus H Metzeler, Daniel Heudobler, Felicitas R Thol, Hermann Einsele, Veit L. Buecklein, Pau Montesinos, Ana Alfonso Pierola, Gala Vega, Eduardo Rodriguez Arboli, Juan Miguel Bergua Burgues, Suhail Chaudhry, Judith Inumerable, Todd Shearer, Laura Liu, Sandeep Kaur, Kaida Wu, Marion Subklewe
Journal: Blood
Blood (2024) 144 (Supplement 1): 2883.1.
https://doi.org/10.1182/blood-2024-201478
Published: 2024
Journal Articles

Perforin-Induced Killing in Leukemic Cells Is Driven By NFAT2-Mediated Cytoskeletal Remodeling

Samuel J. Holzmayer, Jonas Mauermann, Sarah M. Greiner, Jonas S. Heitmann, Kübra Kaban, Helmut R. Salih, Melanie Maerklin
Journal: Blood
Blood (2024) 144 (Supplement 1): 1406.
https://doi.org/10.1182/blood-2024-207673
Published: 2024
Journal Articles

First-in-Human Phase I Dose Escalation and Expansion Study Evaluating the Fc Optimized FLT3 Antibody Flysyn in Acute Myeloid Leukemia Patients with Minimal Residual Disease

Jonas S. Heitmann, MD, Daniela Dörfel, MD, Sabine Kayser, MD, Michael Heuser, Felicitas Thol, Silke Kapp-Schwoerer, MD, Wolfgang Bethge, MD, Ludger Grosse-Hovest, Martin Steiner, Melanie Märklin, PhD, Juliane S. Walz, MD, Richard F. Schlenk, Gundram Jung, MD, Helmut R. Salih
Journal: Blood
Blood (2020) 136 (Supplement 1): 8–9.
https://doi.org/10.1182/blood-2020-139493
Published: 2020
Journal Articles

Interim Results of a First in Man Study with the Fc-Optimized FLT3 Antibody Flysyn for Treatment of Acute Myeloid Leukemia with Minimal Residual Disease

Sabine Kayser, MD, Jonas S. Heitmann, MD, Daniela Dörfel, MD, Felicitas Thol, MD, Michael Heuser, MD, Melanie Märklin, PhD, Carsten Müller-Tidow, MD, Martin Steiner, Ludger Grosse-Hovest, Gundram Jung, MD, Richard F. Schlenk, MD, Helmut R. Salih, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3928.
https://doi.org/10.1182/blood-2019-125327
Published: 2019
Journal Articles

Knock-Down of the NFAT2 Long and Intermediate Isoforms Leads to CLL Acceleration

Jonas S Heitmann, MD, Melanie Märklin, PhD, Posdorowkin Anastasia, B.Sc, Alexander R Fuchs, M.Sc., Felicia M Truckenmüller, Hans-Georg Kopp, MD, Lothar Kanz, MD, Anjana Rao, PhD, Stefan Wirths, MD, Martin R Mueller, MD PhD
Journal: Blood
Blood (2016) 128 (22): 4371.
https://doi.org/10.1182/blood.V128.22.4371.4371
Published: 2016
Journal Articles

NFAT2 Regulates Anergy Induction in CLL through Lck

Melanie Märklin, M. Sc., Jonas S. Heitmann, B. Sc., Alexandra Poljak, B. Sc., Stefanie Bugl, PhD, Hans-Georg Kopp, MD, Michael Haap, MD, Lothar Kanz, MD, Anjana Rao, PhD, Stefan Wirths, MD, Martin R. Müller, MD PhD
Journal: Blood
Blood (2014) 124 (21): 720.
https://doi.org/10.1182/blood.V124.21.720.720
Published: 2014
Journal Articles

Transcriptional Mistargeting Of NFAT2 In CLL

Melanie Märklin, M. Sc., Jonas S. Heitmann, B. Sc., David Worbs, B. Sc., Alexandra Poljak, B. Sc., Claude Evouna, MD, Hans-Georg Kopp, MD, Lothar Kanz, MD, Anjana Rao, PhD, Stefan Wirths, MD, Martin R Müller, MD, PhD
Journal: Blood
Blood (2013) 122 (21): 4122.
https://doi.org/10.1182/blood.V122.21.4122.4122
Published: 2013
Journal Articles

NFAT2 Is a Critical Regulator Of Anergy Induction In CLL

Melanie Märklin, M. Sc., Jonas S. Heitmann, B. Sc., David Worbs, B. Sc., Alexandra Poljak, B. Sc., Claude Evouna, MD, Hans-Georg Kopp, MD, Lothar Kanz, MD, Anjana Rao, PhD, Stefan Wirths, MD, Martin R Müller, MD, PhD
Journal: Blood
Blood (2013) 122 (21): 869.
https://doi.org/10.1182/blood.V122.21.869.869
Published: 2013
Journal Articles

Genetic Loss of NFAT2 Induces Profound Acceleration of CLL in the TCL1 Mouse Model

Melanie Märklin, M. Sc., Stefanie Bugl, M. Sc., Jonas S. Heitmann, B. Sc., Alexandra Poljak, B. Sc., Bettina S, Hackl, B. Sc., Hans-Georg Kopp, MD, Lothar Kanz, MD, Anjana Rao, PhD, Stefan Wirths, MD, Martin R Müller, MD, PhD
Journal: Blood
Blood (2012) 120 (21): 862.
https://doi.org/10.1182/blood.V120.21.862.862
Published: 2012
Journal Articles

Overexpression and Aberrant Nuclear Translocation of NFAT2 in CLL

Jonas S. Heitmann, B. Sc., Melanie Märklin, M. Sc., Alexandra Poljak, B. Sc., Bettina S, Hackl, B. Sc., Juliane Sarah Stickel, MD, Lothar Kanz, MD, Hans-Georg Kopp, MD, Stefan Wirths, MD, Martin R Müller, MD, PhD
Journal: Blood
Blood (2012) 120 (21): 3909.
https://doi.org/10.1182/blood.V120.21.3909.3909
Published: 2012